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650 X.-W. Pan et al.metastasis rate was no statistical difference between the two groups (OR Z 1.63). RFA is a
suitable therapeutic option for older patients and those at high risk for SRCC because of a
low risk of operation and better preservation of renal function.
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There were 65,150 new cases of, and 13,680 deaths from,
kidney cancer based the 2013 cancer incidence statistics
estimated in the United States; meanwhile, kidney cancer
was the second leading cause of urinary cancer-related
death [1]. It is well known that renal cell cancer (RCC) is the
most common form of kidney cancer. The widespread use of
routine abdominal imaging technologies including ultra-
sound, computed tomography (CT), and magnetic resonance
imaging (MRI) in recent years has made it possible to di-
agnose asymptomatic small renal cell cancer (SRCC) earlier
[2], and > 50% of SRCC can be diagnosed at Stage T1a [3].
According to the 2010 Update European Association of
Urology (EAU) Guidelines [4], surgery is the only curative
treatment for RCC. For T1 SRCC, surgical treatment mo-
dalities have evolved from radical nephrectomy to
nephron-sparing surgery (NSS). The EAU Guidelines on Renal
Cell Carcinoma recommend NSS as the treatment of choice
for RCC, though open partial nephrectomy (PN) remains the
gold standard [4]. Generally speaking, PN requires a period
of overall renal ischemia, and a prolonged duration (> 30
minutes) of ischemia would subject the kidneys to possible
ischemic insults, resulting in hemorrhage and decreasing
renal function [5]. However, it is difficult to perform PN in
cancer patients with comorbid disease [6]. These adverse
factors of PN have encouraged investigators to develop a
new, safe, and effective surgical option instead of PN.
Radiofrequency ablation (RFA) has been increasingly
accepted as a potentially promising nephron-sparing,
minimally invasive therapeutic option for patients with
small localized renal masses. In addition, RFA as a primary
or adjuvant treatment modality has been widely used in
solid tumors such as hepatocellular carcinoma, lung cancer,
breast cancer, and RCC [7]. In 1997, Zlotta et al [8] re-
ported the first clinical use of renal RFA for the treatment
of localized renal masses. RFA destroys the kidney tumor
mass in situ by using a high-frequency alternating current
to heat a volume of tissue [9]. RFA, as an outpatient pro-
cedure, can be carried out by open, laparoscopic, and
percutaneous approaches. In addition, RFA avoids ischemic
insults and incises the renal parenchyma compared with
PN.
However, it is still a topic of controversy regarding the
superiority of RFA versus PN for management of SRCC
masses. Based on the literature currently available, ther-
mal ablation has several advantages, including preservation
of renal function, decreased perioperative mortality, faster
postoperative recovery, and reduced postoperation fre-
quency of cardiovascular events [10]. Because of the lack of
randomized controlled trials, all studies that we searchedwere retrospective, nonrandomized, observational studies.
Therefore, the evidence in the current literature is low and
whether RFA can replace PN for special patient needs to be
studied further. The main aim of this meta-analysis is to
collect the existing literature that makes comparisons be-
tween RFA and PN and performs cumulative analyses on
perioperative, renal function, and oncological outcomes in
an attempt to evaluate the overall safety and efficacy of
RFA versus PN for SRCC.
Methods
Literature search
A systematic search was carried out using electronic data-
bases, including PubMed, Google Scholar, Embase, Web of
Science, and the Cochrane library. The search was per-
formed until August 2015, and only articles published in the
English language were considered. A hand-search of the
reference lists of relevant articles was also conducted. The
combination of the following words was used “partial ne-
phrectomy”, “PN”, “radiofrequency ablation”, “RFA”. All
eligible studies were included for further screening.
Study selection
Inclusion and exclusion criteria of studies were identified
before the literature search. All eligible studies were
included if they met the following criteria: (1) studies
comparing RFA with PN with respect to perioperative
outcomes and renal function outcomes and survival; and
(2) patients with renal masses in the normal kidney or
solitary kidney as defined by ultrasonography, CT, or MRI.
Patients with comorbidities who underwent RFA were also
included. Exclusion criteria were as follows: studies
without conducting comparisons between RFA and PN; and
patients with distant metastasis, vascular invasion, he-
reditary renal cancer syndromes, and bilateral or meta-
chronous tumors who were followed up for < 1 year. Study
selection was independently performed by two reviewers
and disagreements in this procedure were resolved by
consensus.
Quality assessment
The Newcastle-Ottawa Scale (NOS) for assessing the
quality of nonrandomized studies in meta-analysis was
used to evaluate the methodological quality of the
enrolled studies. The NOS known as a “star system” in-
cludes three broad perspectives: study group selection
RFA vs. PN for SRCC 651(4 items), group comparability (2 items), and outcome
ascertainment (3 items) [11]. The score of NOS ranges
between one and nine stars. Two reviewers independently
carried out the quality assessment and had discussions
about any disagreement.Figure 1. Flowchart showing screening studies for the meta-
analysis.Data extraction
Two reviewers independently carried out data extraction
by searching the full texts of included studies. The
extracted data were authors, journal and publication year,
number of patients, age, tumor size, comorbid disease,
length of hospital stay, pre- and postoperative estimated
glomerular filtration rate (eGFR), major and minor com-
plications, tumor recurrence and metastasis, overall sur-
vival (OS), local recurrence-free survival (RFS), cancer-
specific survival (CSS), disease-free survival (DFS), and
costs.Table 1 Baseline characteristics of included studies.
Study Treatment No. of
patients
Age
(year)
Tumor size
(cm)
Baseline eGFG
(ml/min/1.73 m2)
Co-morbid disease Publication
typeDM
(%)
Hypertension
(%)
Cardiovascular
disease (%)
Thompson 2015 [28] PN 1057 60.1 2.5 d d d d Non-RCT
RFA 180 70.1 2.1 d d d d
Chang 2015 [29] PN 134 53.9 4.0 105.7 d d d Non-RCT
RFA 134 56.6 3.6 97.2 d d d
Youn 2013 [14] PN 14 53.9 2.4 72.91 d d d Non-RCT
RFA 41 59.2 2.3 73.75 d d d
Psutka 2013 [15] PN 194 57.4 2.6 d d d d Non-RCT
RFA 186 71.4 3.1 d d d d
Pilkington 2013 [16] PN 12 64.4 5.2 63.0 d d d Non-RCT
RFA 18 71.2 5.2 59.6 d d d
Faddegon 2013 [17] PN 205 54.3 3.1 80.7 18.0 50.7 d Non-RCT
RFA 142 61.3 2.3 75.0 18.3 42.2 d
Sung 2012 [18] PN 110 53.4 2.2 89.7 9.1 20.9 0.9 Non-RCT
RFA 40 59.8 2.4 75.2 12.5 47.5 10.0
Olweny 2012 [19] PN 37 54.8 2.5 d d d d Non-RCT
RFA 37 63.8 2.1 d d d d
Takaki 2010 [20] PN 10 64.0 1.9 68.6 20.0 30.0 Non-RCT
RFA 51 69.4 2.4 49.2 19.6 68.6
Raman 2010 [21] PN 42 59.6 3.5 55.9 d d d Non-RCT
RFA 47 65.9 2.7 46.5 d d d
Iwamoto 2010 [22] PN 23 64.1 2.2 57.3 13.0 4.34 8.69 Non-RCT
RFA 30 68.6 2.2 59.9 10.0 20.0 13.3
Turna 2009 [23] PN 36 60.3 3.7 65.0 d d d Non-RCT
RFA 29 60.7 2.6 53.2 d d d
Bird 2009 [24] PN 33 57.8 2.8 82.3 d d d Non-RCT
RFA 36 75.2 3.1 62.8 d d d
Lucas 2008 [25] PN 85 56.2 2.6 70.9 14.1 44.7 d Non-RCT
RFA 86 61.5 2.3 73.4 20.9 46.5 d
Stern 2007 [26] PN 37 56.4 2.4 d d d d Non-RCT
RFA 40 60.5 2.4 d d d d
Bensalah 2007 [27] PN 50 56.5 2.6 d d d d Non-RCT
RFA 38 62.0 2.3 d d d d
Data presented as mean or rate. eGFR Z estimated glomerular filtration rate; DM Z diabetes mellitus; RCT Z randomized controlled
trial.
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652 X.-W. Pan et al.Statistical analysis
A meta-analysis was performed to evaluate the overall ef-
ficacy of RFA and PN. Tests for homogeneity were per-
formed by the Cochrane Inconsistency (Ｉ2) and Chi-square
tests. A value of p < 0.10 shows heterogeneity of enrolled
studies, whereasＩ2＜ 50% shows acceptable heterogene-
ity. Dichotomous variables and continuous variables were
pooled by odds ratio (OR) and weighted mean difference
(WMD), respectively. The fixed-effects model (Mantel-
Haenszel method) [12] was used to calculate pooled esti-
mates for homogeneous studies, and the random-effects
model (DerSimonian-Laird method) [13] was applied for
heterogeneous studies. The pooled effects were measured
by means of Z-test, and p  0.05 was considered statisti-
cally significant. We used Review Manager (RevMan 5.2,
Cochrane Collaboration, Oxford, England) to complete data
analysis.T
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1Results
Description of studies
After a systemic literature search of PubMed, Google
Scholar, Embase, Web of Science, and the Cochrane library,
a total of 283 relevant studies were identified for further
screening. Finally, 16 studies [14e29] were included. The
process of identification and the eligibility of the included
studies are shown in Figure 1. Table 1 shows the baseline
characteristics of the enrolled studies. The result of quality
assessment of the included studies by NOS is represented in
Table 2. Nine studies that were considered as high quality
won a score of nine stars and the remaining seven studies
were scored eight stars on account of insufficient follow-
up.
The patients treated with RFA were significantly older
than that of patients treated with PN [WMD Z 5.07 years,
95% confidence interval (CI): 3.50e6.64, p < 0.00001;
Figure 2). The tumor size was similar between the two
groups (WMD Z 0.20, 95% CI: 0.41e0.02, p Z 0.07;
Figure 2). In addition, more patients in the RFA group had
cardiovascular disease than those in the PN group before
treatment (OR Z 4.24, 95% CI: 1.57e11.47, p Z 0.004),
whereas there was no statistically significant difference in
comorbid diseases including diabetes mellitus (DM) and
hypertension between the two groups (DM: ORZ 1.27, 95%
CI: 0.86e1.87, pZ 0.24; hypertension: ORZ 1.52, 95% CI:
0.67e3.43, p Z 0.32; Figure 3).
Perioperative outcomes
According to statistical analysis, RFA was associated with a
shorter length of hospital stay compared with PN
(WMD Z 2.02 days, 95% CI: 2.82-1.22, p < 0.00001;
Figure 4). Eight studies [14,18,20,23,24,26,27,29] reported
postoperative complications for both RFA and PN. Of them,
seven studies [14,18,23,24,26,27,29] provided data
regarding major complications (Grades III-V of Clavien-
Dindo classification [30]), and five studies
[20,23,24,26,27] provided data on minor complications
Figure 2. Pooled estimates of (A) age and (B) tumor size.
RFA vs. PN for SRCC 653(Grades I and II). No significant difference was found in
major and minor complications between the two groups
(major: OR Z 0.74, 95% CI: 0.35e1.55, p Z 0.42; minor:
ORZ 0.45, 95% CI: 0.11e1.88, pZ 0.27; Figure 4). With its
various surgical approaches, the cost comparison of NSS
techniques for renal tumors is shown in the Discussion
section.
Renal function outcomes
Eleven studies [14,16e18,20e25,29] reported renal func-
tion outcomes, and six studies [16,17,18,22,23,29] pro-
vided data available for meta-analysis. Preoperative eGFR
in patients who were treated with RFA was significantly
lower than that in patients who underwent PN
(WMD Z 7.27, 95% CI: 11.99-2.55, p Z 0.003;
Figure 5). However, there was no significant difference in
postoperative eGFR between the two groups
(WMD Z 1.18, 95% CI: 7.13-4.77, p Z 0.70; Figure 5).
The mean eGFR decline in the RFA group was significantly
lower than that in the PN group (WMD Z 4.82, 95% CI:
9.33-0.31, p Z 0.04; Figure 5).
Survival
Eleven studies [14,15,19e21,23,25e29] reported onco-
logical outcomes. Two studies [14,20] showed none of
patients with local tumor recurrence between the twogroups, and six studies [14,15,21,25e27] reported no
distant metastases between the two groups. The local
tumor recurrence rate in the RFA group was higher than
that in the PN group (OR Z 1.81, 95% CI: 1.14e2.88,
p Z 0.01; Figure 6). However, the distant metastasis rate
was similar between the two groups (OR Z 1.63, 95% CI:
0.74e3.58, p Z 0.22; Figure 6). Given the differences in
the follow-up duration, there was no consensus on the
duration of OS, local RFS, DF, and CSS among the studies
included, and therefore these variables were not consid-
ered in this meta-analysis.Discussion
With advances in surgical technologies, NSS has been
increasingly accepted in the management of RCC, thus
providing new opportunities for both the surgeon and the
patient to choose a more appropriate treatment. PN as a
standard treatment option is extremely effective in the
surgical treatment of SRCC. However, RFA, a less invasive
and nephron-sparing technique, has been rapidly adopted
in patients with SRCC. Potential conditions of patient se-
lection for RFA can be divided into two categories: (1) pa-
tients who are considered poor surgical candidates because
of inadequate renal function and/or comorbid disease, such
as a solitary functional or anatomic kidney, coronary artery
disease, cardiomyopathy, or chronic obstructive pulmonary
Figure 3. Pooled estimates of (A) cardiovascular disease, (B) diabetes mellitus, and (C) hypertension.
654 X.-W. Pan et al.disease, and (2) patients with a high risk of RCC recurrence
as genetic syndromes [31].
For choosing a suitable operation method, perioperative
outcomes, renal function outcomes, and oncological out-
comes are important points in preoperative evaluation.
However, only a few studies in the literature compared RFA
and PN. The result of the current meta-analysis showed
that RFA is safe and feasible for the management of SRCC in
high-risk patients.
The AUA guidelines [32] recommend thermal ablation as
the treatment of choice for patients with comorbid diseases
including DM, hypertension, chronic renal failure, cere-
brovascular disease, and cardiovascular disease. In other
words, RFA is more suitable for patients who have high
surgical or anesthetic risks. Our meta-analysis demon-
strated that patients with SRCC who underwent RFA were
usually older and had more cases of cardiovascular disease
as compared with those who underwent PN. However, there
was no significant difference in DM and hypertension be-
tween the two groups. Arnoux et al [33] reported the
similar finding that patients who underwent RFA were older
and had a higher American Society of Anesthesiologists
score and a lower RENAL (Radius, Exophytic, Nearness,Anterior, Location) score compared with patients who un-
derwent PN.
Our meta-analysis showed that the major and minor
complication rate as important perioperative outcomes
in RFA patients was no significant difference from that
in PN patients. Johnson et al [34] reported that the
major and minor complication rate of 133 cases under-
going RFA was 2.2% and 6.0%, respectively, and the most
common complications were probe-site pain and pares-
thesia. Arnoux et al [33] revealed that the incidence of
overall complications in the RFA group was significantly
lower than that in the PN group (6.3% vs. 29.4%). How-
ever Carey and Hakky [35] showed no significant dif-
ference between the two groups in terms of
complications.
As is known to all, renal functional preservation should
be the most important goal for patients with SRCC, espe-
cially for patients with poor renal function before surgery.
Pettus et al [36] found that baseline tumor size or location
did not affect postoperative renal function, but preopera-
tive eGFR did affect postoperative renal function. It was
found in our meta-analysis that preoperative eGFR in the
RFA group was lower than that in the PN group, whereas
Figure 4. Pooled estimates of (A) hospital stay, (B) major complications, and (C) minor complications.
RFA vs. PN for SRCC 655there was no significant difference in postoperative eGFR
between the two groups. Interestingly, the mean decline in
GFR presented a significant difference between the RFA
and PN groups (RFA vs. PN: 14.8 vs. 25.5, p Z 0.04), sug-
gesting that RFA showed better preservation of renal
function compared with PN. Similarly, in the study of
Raman and colleagues [21], the maximize renal function
preservation favored RFA group, and the 0-3 months and 12
months median GFP declines in RFA versus PN groups were
7.1 mL/min/1.73 m2 versus 15.8 mL/min/1.73 m2 and
11.2 mL/min/1.73 m2 versus 22.4 mL/min/1.73 m2,
respectively. By contrast, Takaki et al [20] reported that
the median baseline GFP in the RFA group was significantly
lower than that in the PN group (49.2 mL/min/1.73 m2 vs.
68.6 mL/min/1.73 m2), but there was no significant dif-
ference in median GFP decline between RFA and PN groups
at the last follow-up (7.9 mL/min/1.73 m2 vs. 11.5 mL/min/
1.73 m2).
In addition, postoperative tumor control is vital to
ensure the effectiveness of treatment. In all includedstudies, there were 43 cases (6.4%) of local tumor recur-
rence in the RFA group versus 53 cases (3.4%) in the PN
group, suggesting that the PN oncological outcome is su-
perior to RFA. However, there was no significant difference
in the items of tumor metastasis between the two groups. A
systematic review [37] reported that the local tumor
recurrence rate in the RFA group was slightly higher than
that in the PN group. A recent study [38] reported local
tumor recurrence in two patients who underwent RFA
versus none in PN. Additionally, Turna et al [23] found that
the OS and CCS (91.2 and 100%) of PN group in the 2 years
following were better than those (83.9 and 83.9%) of RFA
group. Conversely, a long-term comparative study [19]
showed that no statistical difference was found in the 5-
year OS, CCS, DFS, and local RFS of RCC patients between
RFA treatment and PN treatment.
Finally, financial issues are of great importance in the
decision to incorporate new technologies. Generally
speaking, new technologies need to spend more than the
conventional standard method. Castle et al [38] reported
Figure 5. Pooled estimates of (A) preoperative estimated glomerular filtration rate (eGFR), (B) postoperative eGFR, and (C)
eGFR decline.
656 X.-W. Pan et al.that the 6-month total median cost for open partial ne-
phrectomy (OPN), robot-assisted partial nephrectomy
(RLPN), laparoscopic radiofrequency ablation, and
computed tomography RFA was $17,018, $20,314, $13,965,
and $6475, respectively. In other words, the cost of either
laparoscopic or CT-guided RFA was lower than that of RLPN
and OPN. In addition, a cost comparison study [39] showed
that the mean total cost of RFA was significantly lower than
that of laparoscopic PN and OPN ($4454 vs. $7767 and
$7013), including surgical supplies, operating room, room
and board, pharmacy, laboratory/pathology, radiology, and
other professional fees. Some studies [30,40] also reported
that RFA was superior to PN in item of costs in patients with
SRCC.
However, there are some limitations in our study. First,
all studies included in this meta-analysis were retrospec-
tive, nonrandomized, and observational studies because of
the absence of prospective and randomized controlled
studies. Second, some variables were unavailable to carry
out meta-analysis because of the lack of standard data,
such as operation duration, estimated blood loss, follow-up
periods, and costs; most of these studies only providedmedian data, range, and interquartile range. Third, survival
analysis of some included studies had no consistent stan-
dard follow-up period. Two studies provided 5-year data;
two studies provided 3-year data; one study provided 2-
year data; and one study provided unclear data.
The results of this study demonstrated that patients
treated with RFA were older and associated with more co-
morbid diseases as compared with patients who underwent
PN. Additionally, RFA has the advantages of a shorter length
of hospital stay, lower costs, and better preservation of
renal function as compared with PN, although they were
equivalent in complication occurrence and renal functional
preservation. The drawback of RFA is that it is associated
with more local tumor recurrence. Therefore, it is impor-
tant for high-risk patients to weigh the low risk of an
operation against the drawback which it may bring. In brief,
RFA is a suitable therapeutic option for older patients and
those at high risk for SRCC because of the low risk of
operation and better preservation of renal function. Pro-
spective and randomized controlled studies are required to
define the role of RFA in the management of small renal
masses.
Figure 6. Pooled estimates of (A) local tumor recurrence and (B) distant metastasis.
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